Přihlásit se Zaregistrujte se zdarma

Příjmy společnosti Æterna Zentaris

Jaká je hodnota metriky Příjmy společnosti Æterna Zentaris?

Hodnota metriky Příjmy společnosti Æterna Zentaris, Inc. je -$18.05

Jaká je definice metriky Příjmy?

Výsledek příjmů pro kmenové akcionáře (Income) se rovná celkovému příjmu sníženému o přednostně vyplacené dividendy.

Net income available to common shareholders are the profits remaining after the company pays all of its suppliers, employees, service providers, creditors, and preferred shareholders. In other words, this is revenue less all expenses and preferred dividends. The number measures common shareholders' claim on the company's cash flows.

Příjmy společností v sektoru Health Care sektor na TSX ve srovnání se společností Æterna Zentaris

Čemu se věnuje společnost Æterna Zentaris?

Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests. Its lead product is macimorelin, an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as oncology indications. The company markets macimorelin under the Macrilen brand name. Aeterna Zentaris Inc. has a license agreement with University Wuerzburg to research, develop, manufacture, and sell a potential COVID-19 vaccine; development, manufacture, and commercialization of the treatment for neuromyelitis optica spectrum disorder; and to develop human 3D intestinal tissue models to study infection biology; and for pre-clinical development towards the potential treatment of Parkinson's disease. It also has a license agreement with Consilient Health Ltd., Novo Nordisk Novo Nordisk Health Care AG, and NK MEDITECH Ltd. for the development and commercialization of macimorelin in the United States and Canada, as well as The University of Sheffield, the United Kingdom for the research, development, manufacture, and commercialization of parathyroid hormone fusion polypeptides for the treatment of primary hypoparathyroidism. Aeterna Zentaris Inc. was incorporated in 1990 and is headquartered in Summerville, South Carolina.

Firmy s metrikou příjmy podobnou společnosti Æterna Zentaris